Education and Training Module for Ohio EMS – Version 2.0.

Slides:



Advertisements
Similar presentations
Education and Training Module for Ohio EMS Developed in the 1960s Opioid antagonist Emergent overdose treatment in the hospital and prehospital settings.
Advertisements

2014 EMR Naloxone Presentation DPH/EMS Program Wisconsin Department of Health Services Naloxone Intranasal Administration in the Pre-hospital Setting –
WREMAC BLS Naloxone In-service
OPIOIDS I. Where do they come from? / synthesized in 1803
Opioid Overdose Prevention for Law Enforcement and First Responders Sponsored by the NC Office of EMS.
Naloxone formulation update
Anaphylaxis and Epinephrine The Role of the EMT-Basic N.H. Patient Care Protocols N.H. Department of Safety Division of Fire Standards & Training and Emergency.
Opioid Rescue Kits for Porter County Sheriff’s Department.
Opioid Overdose Prevention South Boston HOPE Initiative.
Saves Lives.
Approved by the Maine EMS Medical Direction and Practices Board. Intranasal Naloxone Administration Training Module for Law Enforcement Officers and Firefighters.
Diabetes – What is it? Hormone (insulin) needed to regulate blood glucose levels is ineffective; Glucose levels can get too high or too low Type I - patients.
STATEWIDE OPIOID ANTAGONIST COMMUNITY ACCESS PROGRAM INTRANASAL NALOXONE ADMINISTRATION TRAINING MODULE Vermont Statewide Opioid Antagonist Program.
Opioid Antagonist Scope of Practice Modification
Illinois EMSC1 Upon completion of this lecture, you will be better able to: n Define shock n Describe key differences between the pediatric and adult circulatory.
Chapter 13 Opioids.
Chapter 16 General Pharmacology.
Allergic Reactions CHAPTER 20. Assessment of Allergic Reactions.
Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.
Pediatric Prehospital Seizure Management: Evidence Based Guidelines and State of Care in CO Kathleen Adelgais, MD MPH Pediatric Emergency Medicine Children’s.
Naloxone Training Program EMR/EMT May 27, 2014
SILVER CROSS EMSS EMD CE September Heroin use is increasing, and so are heroin-related overdose deaths.
General Pharmacology.
Limmer et al., Emergency Care, 10 th Edition © 2005 by Pearson Education, Inc. Upper Saddle River, NJ CHAPTER 20 Allergic Reactions.
The Opiate Crisis in Rural America Carol A. Cunningham, M.D., FAAEM, FACEP State Medical Director Ohio Department of Public Safety, Division of EMS Associate.
1 Medical Emergencies. 2 Objectives Describe the potential causes and outline the management of seizures in children Discuss the implication of fever.
EMR INTRANASAL NALOXONE Vermont Statewide EMS Protocol Education.
1 Medical / Behavioral Problems Diabetic Emergencies Altered Mental Status.
Combating the Opioid Abuse Epidemic with Evzio ® (naloxone) Baely Crockett, PharmD Eskenazi Health Internal Medicine PGY2 This speaker has no actual or.
OPIOIDS I. Where do they come from? –poppy plant: from middle east and Asia –dried sap from plant is opium; cultivated annually BUT plant produces drug.
Naloxone use Objectives  In this slide set, you will learn: What naloxone (Narcan) is How it works when administered to a person who has overdosed on.
MBEMSC /PIER Committee
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Grampian Naloxone Programme
There may be a title here that come from the foundation.
NALOXONE Presented by The RASE Project. Scope Of The Problem Opiate overdose is a major public health problem in the United States. Overdoses have increased.
Naloxone: Prescribing and Dispensing
Ill Naloxone February 7 th, 2015 Tom Rafferty. Opioid Dependency & Overdose Emergency Interventions For Overdose Future Of Naloxone Questions Rescue Kits.
Firefighter Emergency First Response Common Medical Emergencies.
First Responder Naloxone Grant Webinar
Naloxone for Entities & Laysavers Aaron Kochar, J.D.
NALOXONE (NARCAN) ADMINISTRATION.  What are opioids?  Who abuses them?  What will an overdose look like?  What is the treatment for opioid overdose?
Naloxone: Saving Lives Cathy Oliphant, PharmD Associate Professor of Pharmacy Practice ISU College of Pharmacy.
Naloxone use Objectives  In this slide set, you will learn: What naloxone (Narcan) is How it works when administered to a person who has overdosed on.
AKA. What the Hell are the Medical Directors Doing? Dan O’Donnell Beech Grove Audit and Review 3/11/08.
and Altered Mental Status
Narcan.
Medication Dosage and Administration
Sierra – Sacramento Valley EMS Agency
Opiod analgesics 9월 흉부외과 인턴 김영재.
The Opioid Epidemic and Naloxone CTSMA 57th Annual Conference
Prescription Drugs.
Education and Training Module for Whatcom County EMS
Opioid Overdose Responder Training
Overdose Prevention and Management
for Peace Officers and EMTs
Wicomico County Local Behavioral Health Authority
Grampian Naloxone Programme
Grays Harbor EMS & Trauma Care Council October 2016
QC Harm Reduction Opioid Overdose Reversal Training
Education and Training Module for Whatcom County EMS
GFR Medication Training
EMT Naloxone Administration
Grampian Naloxone Programme
Act Naloxone Availability
Approved by the Maine EMS Medical Direction and Practices Board.
Emergency Medical Services Program
QC Harm Reduction Opioid Overdose Reversal Training
OVERDOSE AWARENESS & NALOXONE TRAIN THE TRAINER
Presentation transcript:

Education and Training Module for Ohio EMS – Version 2.0

Developed in the 1960s Opioid antagonist Emergent overdose treatment in the hospital and prehospital settings Increased demand for naloxone - Greater variety of available opioids - Increased opioid use and abuse

Buprenorphine Codeine Fentanyl Hydrocodone Hydromorphone Methadone Morphine Oxycodone

Lorcet®, Lortab®, Norco®, Vicodin®: Hydrocodone + acetaminophen Percocet®: Oxycodone + acetaminophen Percodan®: Oxycodone + aspirin Suboxone®: Buprenorphine + naloxone Opium Heroin

Oral Transcutaneous Intravenous Subcutaneous (“skin popping” during the abuse of opioids)

Miosis (pinpoint pupils) Decreased intestinal motility Respiratory depression Decreased mental status

Hypoxia Hypercarbia Aspiration Cardiopulmonary arrest The incidence of risk factors increases when other substances such as alcohol, benzodiazepines, or other medications have also been taken by the patient

Naloxone displaces the opioid from the opioid receptor in the nervous system Opioid receptor Opioid Naloxone

This may result in the sudden onset of the signs and symptoms of opioid withdrawal Agitation Tachycardia Pulmonary edema Nausea Vomiting Seizures

Endotracheal Intramuscular Intranasal Intravenous

Equivalent clinical efficacy compared to intravenous naloxone Intravenous access may be impossible to establish in chronic intravenous drug abusers

Intranasal atomizers facilitate immediate administration of naloxone Reduction in the risk of needle stick injury and associated potential infectious disease exposure

Contains a pre-measured dose of medication which reduces the risk of dosing errors Designed for self-administration of medication by patients and laypersons

Contains a pre-measured dose of medication which reduces the risk of dosing errors Designed for self-administration of medication by patients and laypersons

On April 16, 2014, the Emergency Medical, Fire, and Transportation Services (EMFTS) Board approved expansion of the Ohio EMS scope of practice to allow emergency medical responders (EMRs) and emergency medical technicians (EMTs) to administer intranasal naloxone and naloxone via auto-injector to persons suspected of suffering from an opioid overdose upon completion of training and with the approval of the medical director

Medical director approval is mandatory Training is mandatory A protocol from the medical director is mandatory

The medical director retains the authority to limit or prohibit the administration of intranasal naloxone or a naloxone auto- injector The administration of naloxone by the endotracheal, intramuscular (exception via an auto-injector), or intravenous routes remains prohibited for EMRs and EMTs

The dose of naloxone to be administered is determined by the medical director Naloxone, in the form of a liquid solution, can be drawn up in a syringe or provided as a pre-filled syringe

The tip of the syringe should be placed near or just inside the nostril Placement of the syringe too far inside the nasal cavity may traumatize the nasal passages or cause epistaxis

Remove the needle from the syringe prior to administration to prevent trauma to the nasal passages or puncture of the nasal tissues or sinuses The use of a mucosal atomization device (MAD) on the tip of the syringe prevents nasal trauma and maximizes the delivery of medication to the patient

Spring-loaded syringe and needle device Contain a pre-measured dose of medication Designed for self-administration of medication by patients or laypersons Delivers medication via the intramuscular or subcutaneous route Activated by application of firm pressure to the patient’s body or by pressing a button on the device

Firm contact of the auto-injector must be maintained against the patient’s skin for 5 to 10 seconds to ensure delivery of the full dose. Never place your thumb or fingers over or near the end of the auto-injector. Hold the auto-injector firmly with a fisted hand before and during the administration of the auto-injector contents to avoid accidental injection of yourself or dispersal of the contents outside of the patient’s body.

Currently, naloxone auto-injectors contain a 0.4 mg/0.4 ml naloxone hydrochloride solution The administration of one auto-injector will deliver naloxone 0.4 mg intramuscularly or subcutaneously to the patient The commercially available cartons of EVZIO® that are currently prescribed to patients and laypersons contain two naloxone auto-injectors and one auto- injector trainer

Sites for Injection

The administration of naloxone may result in the rapid onset of the signs and symptoms of opioid withdrawal Agitation Tachycardia Pulmonary edema Nausea Vomiting Seizures

Prior to the administration of naloxone by all EMS providers, all patients should initially receive the appropriate medical interventions to provide support of their airway, breathing, and circulation (ABCs)

All patients should be assessed for other causes of altered mental status and/or respiratory depression (hypoxia, hypoglycemia, head injury, shock, stroke) The adverse effects following naloxone administration, particularly in chronic opioid users and abusers, may place the patient and bystanders at risk

Due to the potential adverse effects of naloxone administration, medical professionals often elect to reserve the administration of naloxone to patients with known or suspected opioid overdoses for -Impending cardiopulmonary arrest -Respiratory depression -Shock

The medical director should include parameters within the protocols for EMRs and EMTs on how to address these adverse effects Agitation Tachycardia Pulmonary edema Nausea Vomiting Seizures

The half-life of naloxone is relatively brief (as short as 30 minutes) All patients who receive naloxone must be monitored closely for recurrent symptoms, including altered mental status, respiratory depression, and circulatory compromise

You respond to a known drug abuser who is found unconscious with a hypodermic needle inserted into her arm. Her pupils are pinpoint and she does not respond to painful stimuli. Upon assessment of vital signs, her blood pressure is 110/70, pulse is 60, respiratory rate is 2, and a pulse oximeter reading of 84%. What is the first action you should take?

This patient is apneic as evidenced by her respiratory rate of 2. The appropriate initial action to take is to open and maintain the airway and administer oxygen via bag valve mask. Therapeutic interventions to support the patient’s airway, breathing, and circulation should be initiated prior to the administration of naloxone.

You respond to the home of a diabetic hospice patient with cancer. He has decreased mental status and pinpoint pupils. His wife checked his blood glucose prior to calling and it is 170. The patient was at his baseline mental status until she applied a transcutaneous fentanyl patch that was recently prescribed for pain control. He has a blood pressure of 130/80, pulse of 70, respiratory rate of 18, and a pulse oximetry reading of 95%. What action should you take?

You should follow the protocol that is provided by your medical director. This patient has stable vital signs. Your medical director may direct you to administer intranasal naloxone or a naloxone auto-injector, remove the fentanyl patch, or transport the patient without any additional medical intervention. The medical director retains the authority to allow, limit, or prohibit the administration of intranasal naloxone or naloxone auto-injectors by EMS providers.